Generate Biomedicines Inc.
GENB | NASDAQ
$13.20
-$1.26 (-8.71%)
Nov 2, 2026, 3:58 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 |
|---|---|---|
Net Income | -222.97M | -181.38M |
Depreciation & Amortization | 13.18M | 15.35M |
Stock-Based Compensation | 20.58M | 19.47M |
Other Working Capital | -12.79M | 24.83M |
Other Non-Cash Items | 3.21M | 702K |
Deferred Income Tax | n/a | n/a |
Change in Working Capital | -14.62M | 28.12M |
Operating Cash Flow | -200.62M | -117.75M |
Capital Expenditures | -3.51M | -3.45M |
Cash Acquisitions | n/a | n/a |
Purchase of Investments | -164.73M | -282.98M |
Sales Maturities Of Investments | 285.01M | 228.69M |
Other Investing Acitivies | n/a | 10K |
Investing Cash Flow | 116.77M | -57.73M |
Debt Repayment | -8.16M | -11.12M |
Common Stock Repurchased | n/a | n/a |
Dividend Paid | n/a | n/a |
Other Financial Acitivies | 14.25M | 6.13M |
Financial Cash Flow | 28.06M | 91.33M |
Net Cash Flow | -55.79M | -84.15M |
Free Cash Flow | -204.13M | -121.2M |
Adj. Free Cash Flow | -224.71M | -140.66M |
Maintenance CapEx | n/a | -3.45M |
Growth CapEx | -3.51M | n/a |
Owner Earnings | -200.62M | -121.2M |
Add to Watchlist
Select watchlists to add or remove GENB